Holen Sie sich die Stockscreener-App
87.45
1.66%
1.43
Handel nachbörslich:
87.45
Soleno Therapeutics Inc Aktie (SLNO) Neueste Nachrichten
What analysts say about Soleno Therapeutics Inc. stockFree Risk Assessment Services - Autocar Professional
Can Soleno Therapeutics (SLNO) Climb 33.11% to Reach the Level Wall Street Analysts Expect? - Yahoo Finance
Here's What Could Help Soleno Therapeutics (SLNO) Maintain Its Recent Price Strength - Yahoo Finance
Soleno Therapeutics Inc. Stock Analysis and ForecastFree Consultation - jammulinksnews.com
Soleno’s Rare Disease Drug Launch Turns Heads On Wall Street - Finimize
What drives Soleno Therapeutics Inc. stock priceExplosive earning power - jammulinksnews.com
Is Soleno Therapeutics Inc. a good long term investmentConsistently high yield - jammulinksnews.com
Soleno Therapeutics’ Vykat XR Exceeds Sales Expectations - MSN
Soleno gains as Betaville cites buyout interest (update) - MSN
(SLNO) Trading Report - news.stocktradersdaily.com
Soleno Therapeutics: A Strategic Capital Raise Balances M&A Optionality with Long-Term Growth Potential - AInvest
Soleno Therapeutics: Fairly Valued Despite M&A Expectations - Seeking Alpha
Soleno Therapeutics (SLNO) Receives a Buy from Oppenheimer - The Globe and Mail
Mintz Advises on Soleno Therapeutics’ $200 Million Public Offering - Mintz
Soleno Therapeutics Shares Dip Following $200 Million Stock Offering Pricing - MSN
Soleno Therapeutics stock dips on proposed $200M offering - MSN
Baird Maintains Soleno Therapeutics(SLNO.US) With Buy Rating, Raises Target Price to $121 - 富途牛牛
Stifel reiterates Buy rating on Soleno Therapeutics stock amid strong Vykat launch - Investing.com Nigeria
Stifel reiterates Buy rating on Soleno Therapeutics stock amid strong Vykat launch By Investing.com - Investing.com South Africa
Soleno Therapeutics Announces Public Stock Offering - TipRanks
In Brief: Soleno To Raise $200m To Boost Vykat XR Launch - insights.citeline.com
Soleno Therapeutics stock soars as Stifel reiterates Buy on strong Vykat sales - Investing.com Australia
Soleno Therapeutics prices $200M public offering - MSN
Baird raises Soleno Therapeutics stock price target to $121 on strong Vykat XR sales By Investing.com - Investing.com South Africa
Soleno Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock - GlobeNewswire
Baird raises Soleno Therapeutics stock price target to $121 on strong Vykat XR sales - Investing.com Nigeria
Firm Advises Soleno Therapeutics on $200 Million Public Offering - Wilson Sonsini
Soleno reports preliminary Q2 revenue of $31-33 million for VYKAT XR - Investing.com Nigeria
Soleno Therapeutics Announces Proposed $200 Million Public Offering of Common Stock - GlobeNewswire
Soleno sales of new Prader-Willi drug rise faster than expected - BioPharma Dive
Soleno Therapeutics Prices $200 Mln Public Offering To Support VYKAT XR Launch - Nasdaq
Soleno Therapeutics stock falls after pricing $200 million offering By Investing.com - Investing.com Canada
Soleno Therapeutics stock falls after pricing $200 million offering - Investing.com
Soleno Therapeutics prices public offering at $85 per share - Investing.com
Soleno Therapeutics prices public offering at $85 per share By Investing.com - Investing.com South Africa
Soleno Therapeutics Secures $200M Public Offering to Commercialize Breakthrough Prader-Willi Treatment - Stock Titan
4.91%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):